Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumours (NSGCT): Final results of phase II trial

被引：0
|
作者：
Tryakin [1 ]
Fedyanin, M. [1 ]
Segeev, Y. [2 ]
Bulanov, A. [1 ]
Matveev, V. B. [3 ]
Volkova, M. [4 ]
Klimov, A. [4 ]
Fainstein, I. [2 ]
Akhmedov, B. [5 ]
Menshikova, S. [6 ]
Zakharova, T. [7 ]
Garin, A. M. [1 ]
Chekini, D. [1 ]
Chekini, A. [5 ]
Sekhina, O. [1 ]
Tjulandin, S. [1 ]
机构：
[1] NN Blokhin Natl Med Res Ctr Oncol, Clin Pharmacol & Chemotherapy Dept, Moscow, Russia
[2] NN Blokhin Natl Med Res Ctr Oncol, Radiosurg Dept, Moscow, Russia
[3] NN Blokhin Russian Canc Res Ctr, Dept Urol, Moscow, Russia
[4] NN Blokhin Natl Med Res Ctr Oncol, Dept Urol, Moscow, Russia
[5] NN Blokhin Natl Med Res Ctr Oncol, Dept Thorac Surg, Moscow, Russia
[6] IM Sechenov First Moscow State Med Univ Sechenov, Dept Oncol, Moscow, Russia
[7] NN Blokhin Natl Med Res Ctr Oncol, Dept Pathol, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
982P
引用
收藏
页数：2
相关论文
共 38 条
  • [1] Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Fainstein, Igor
    Garin, Avgust
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Dose-dense BEP (ddBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Safety results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Feinstein, Igor
    Garin, August
    Tjuiandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Paclitaxel plus BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis; A phase II study.
    Tryakin, A.
    Fedyanin, M.
    Sergeev, U.
    Pokataev, I.
    Ahmedov, B.
    Zakharova, T.
    Mitin, A.
    Fainstein, I.
    Garin, A.
    Tjulandin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Paclitaxel plus BEP (T-BEP) Regimen as Induction Chemotherapy in Poor Prognosis Patients With Nonseminomatous Germ Cell Tumors: A Phase II Study
    Tryakin, A.
    Fedyanin, M.
    Kanagavel, D.
    Fainstein, I.
    Sergeev, J.
    Polockij, B.
    Matveev, V.
    Zakharova, T.
    Garin, A.
    Tjulandin, S.
    UROLOGY, 2011, 78 (03) : 620 - 625
  • [5] C-BOP-3BEP as induction chemotherapy (CT) in nonseminomatous germ cell tumor (NSGCT) patients with poor prognosis.
    Tryakin, A
    Tjulandin, S
    Titov, D
    Zakharova, T
    Figurin, K
    Feinstein, I
    Garin, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 443S - 443S
  • [6] THE ANZUP PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS
    Long, A.
    Toner, G. C.
    Stockler, M.
    Thompson, D. B.
    Gebski, V.
    Yip, S.
    King, M.
    Friedlander, M.
    Quinn, D.
    Singhal, N.
    Roncolato, F.
    Grimison, P. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 61 - 62
  • [7] Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
    Zebic, Danka
    Stockler, Martin
    Martin, Andrew
    Pashankar, Farzana
    Tran, Ben
    Mazhar, Danish
    Huddart, Robert
    Wheater, Matthew
    Walpole, Euan
    Dunwoodie, Elaine
    Feldman, Darren
    Birtle, Alison
    Stevanovic, Amanda
    Wyld, David
    Hanning, Fritha
    Grimison, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 51 - 51
  • [8] A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS: THE P3BEP TRIAL (ANZUP 1302)
    Lawrence, Nicola
    Toner, Guy
    Martin, Andrew
    Stockler, Martin
    Yeung, Annie
    Wong, Nicole
    Thomson, Damien
    Gebski, Val
    Yip, Sonia
    King, Madeleine
    Friedlander, Michael
    Quinn, David
    Tan, Thean Hsiang
    Chan, Howard
    Hanning, Fritha
    Weickhardt, Andrew
    Jeffery, Mark
    Stevanovic, Amanda
    Hovey, Elizabeth
    Wyld, David
    Davis, Ian
    Grimison, Peter
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 146 - 147
  • [9] Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study
    Israelyan, E. R.
    Tryakin, A.
    Rumyantsev, A.
    Fedyanin, M.
    Tyulyandina, A.
    Klimov, A.
    Matveev, V.
    Volkova, M. I.
    Paychadze, A.
    Bychkov, Y.
    Yunaev, G.
    Tsareva, A.
    Tikhomirova, T.
    Zorinova, A.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S543 - S543
  • [10] Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
    Nicola J. Lawrence
    Howard Chan
    Guy Toner
    Martin R. Stockler
    Andrew Martin
    Sonia Yip
    Nicole Wong
    Annie Yeung
    Danish Mazhar
    Farzana Pashankar
    Lindsay Frazier
    Ray McDermott
    Roderick Walker
    Hsiang Tan
    Ian D. Davis
    Peter Grimison
    BMC Cancer, 18
1234